Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour

Andrew J. Wagner, Mark Agulnik, Michael C. Heinrich, Daruka Mahadevan, Richard F. Riedel, Margaret Von Mehren, Jonathan Trent, George D. Demetri, Christopher L. Corless, Murray Yule, John F. Lyons, Aram Oganesian, Harold Keer

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Background: Gastrointestinal stromal tumours (GIST) treated with the tyrosine kinase inhibitor (TKI) imatinib can become resistant when additional mutations in the receptor tyrosine kinases KIT or PDGFRA block imatinib activity. Mutated KIT requires the molecular chaperone heat-shock protein 90 (HSP90) to maintain stability and activity. Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor. We hypothesised that the combination of onalespib and imatinib may be safe and effective in managing TKI-resistant GIST. Patients and methods: In this dose-escalation study, we evaluated the safety and efficacy of combination once-weekly intravenous onalespib for 3 weeks and daily oral imatinib in 28-d cycles. Twenty-six patients with TKI-resistant GIST were enrolled into four sequential dose cohorts of onalespib (dose range, 150-220 mg/m2) and imatinib 400 mg. The relationship between tumour mutational status (KIT/PDGFRA) and efficacy of treatment was explored. Results: Common onalespib-related adverse events were diarrhoea (58%), nausea (50%), injection site events (46%), vomiting (39%), fatigue (27%), and muscle spasms (23%). Overall, 81% of patients reported more than one onalespib-related gastrointestinal disorder. Nine patients (35%) had a best response of stable disease, including two patients who had KIT mutations known to be associated with resistance to imatinib and sunitinib. Disease control at 4 months was achieved in five patients (19%), and median progression-free survival was 112 d (95% confidence interval 43-165). One patient with PDGFRA-mutant GIST had a partial response for more than 376 d. Conclusion: The combination of onalespib plus imatinib was well tolerated but exhibited limited antitumour activity as dosed in this TKI-resistant GIST patient population.

Original languageEnglish (US)
Pages (from-to)94-101
Number of pages8
JournalEuropean Journal of Cancer
Volume61
DOIs
StatePublished - Jul 1 2016

Keywords

  • Non-ansamycin HSP90 inhibitor
  • Onalespib (AT13387)
  • TKI-resistant GIST

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour'. Together they form a unique fingerprint.

  • Cite this

    Wagner, A. J., Agulnik, M., Heinrich, M. C., Mahadevan, D., Riedel, R. F., Von Mehren, M., Trent, J., Demetri, G. D., Corless, C. L., Yule, M., Lyons, J. F., Oganesian, A., & Keer, H. (2016). Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. European Journal of Cancer, 61, 94-101. https://doi.org/10.1016/j.ejca.2016.03.076